Following A 6.04% Weekly Incline, Is It Still A Buy For Tscan Therapeutics Inc (NASDAQ: TCRX)?
Tscan Therapeutics Inc (NASDAQ:TCRX)’s traded shares stood at 0.46 million during the last session, with the company’s beta value hitting 1.01. At the close of